• Ahima RS, Dushay J, Flier S, Prabakaran D, Flier JS: Leptin accelerates the onset of puberty in normal female mice. J Clin Invest. 99:391–395, 1997.
• Ahima RS, Flier JS: Leptin. Annu Rev Physio. 62:413-37, 2000.
• Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell BB, Maratos-Flier E, Flier JS.: Role of leptin in the neuroendocrine response to fasting. Nature. 382:250–52, 1996.
• Antal A, Beniczky S, Kincses TZ, Jakab K, Benedek Gy, Vecsei L: Perceptual cate-gorization is impaired in Huntington’s disease: an electrophysiological study. Dement Geriatr Cogn Disord. 16:187–192, 2003.
• Barbeau A, Duvoisin RC, Gerstenbrand F, Lakke JP, Marsden CD, Stern G: Clas-sification of extrapyramidal disorders. Proposal for an international clasClas-sification and glossary of terms. J Neurol Sci. 51:311-327, 1981.
• Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, Martin JB: Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann Neurol. 23:562-9, 1988.
• Bjorbaek C, Elmquist JK, Michl P, Ahima RS, van Bueren A, McCall AL, Flier JS: Expression of leptin receptor isoforms in brain microvessels. Endocrinology.
139:3485–91, 1998.
• Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P, Mulder H: Progressive alterations in the hypo-thalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's di-sease. Hum Mol Genet. 15:1713-1721, 2006.
• Brabant G, Müller G, Horn R, Anderwald C, Roden M, Nave H: Hepatic leptin signaling in obesity. FASEB Journal. 19:1048-1050, 2005.
• Brabant G, Nave H, Horn R, Anderwald C, Müller G, Roden M: In vivo and in vit-ro evidence for a hepatic modulation of the leptin signal in rats. Euvit-ropean Journal of Clinical Investigation 34:831–837, 2004.
Literaturverzeichnis 50
• Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA: Trinucleotide repeat length and clinical progression in Huntington’s disease. Neurology. 46:527–531, 1996.
• Bray GA, York DA: Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev. 59:719–90, 1979.
• Brunner L, Nick HP, Cumin F, Chiesi M, Baum HP, Whitebread S, Stricker-Krongrad A, Levens N: Leptin is a physiologically important regulator of food intake.
Int J Obes Relat Metab Disord. 21:1152-60, 1997.
• Bruyn GW, Went LN: Huntington’s chorea. In: Vinken PJ, Bruyn GW, Klawans HL:
Handbook of Clinical Neurology 2. Elsevier. 5:267-313, 1986.
• Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB pro-tein: evidence for a peripheral signal linking adiposity and central neural networks. Sci-ence. 269:546-549, 1995.
• Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS:
Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex ste-roids, and leptin: observational and interventional studies in humans. Diabetes.
51:2105–2112, 2002.
• Chan LJ, Blüher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS:
Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids and leptin: observational and interventional studies in humans. Diabetes. 51:2105-2112, 2002.
• Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP:
Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 84:491-495, 1996.
• Chua SC, Chung WK, Wu-Peng XS: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 271:994–96, 1996.
• Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreac-tive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 334:292-295, 1996.
Literaturverzeichnis 51
• Cowley M, Smith R, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Men-dez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL: The distribution and mechanism of action of ghrelin in the CNS demons-trates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 37:649–666, 2003.
• Currier RD, Jackson JF, Meydrech EF: Progression rate and age at onset are related in autosomal dominant neurologic diseases. Neurology. 32:907–909, 1982.
• Dawbarn D, De Quidt ME, Emson PC: Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 340:251-60, 1985.
• Djoussé L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH: Weight loss in early stage of Huntington’s disease. Neurology. 59:1325–30, 2002.
• Dorner JL, Miller BR, Barton SJ, Brock TJ, Rebec GV: Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's di-sease. Behav Brain Res. 178:90-7, 2007.
• Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C, Bloom SR: Ghrelin increases food intake in obese as well as lean subjects. Int J Obes. 29:1130-6, 2005.
• Elmquist JK, Ahima RS, Elias CS, Flier JS, Saper CB: Leptin activates distinct pro-jections from the dorsomedial and ventromedial hypothalamic nuclei. Proc Natl Acad Sci. 741–48, 1998.
• Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, Saper CB: Leptin activates neu-rons in the ventrobasal hypothalamus and brainstem. Endocrinology. 839–42, 1997.
• Elmquist JK, Bjorbaek C, Ahima RS, Flier JS: Distributions of leptin receptor iso-forms in the rat brain. J Comp Neurol. 395:535–47, 1998
• Fain J, del Mar N, Meade C, Reiner A, Goldowitz D: Abnormalities in the function-ing of adipocytes from R6/2 mice that are transgenic for Huntfunction-ington’s disease mutation.
Human Molecular Genetics. 10:145–152, 2001.
• Farrer LA, Meaney FJ: An anthropometric assessment of Huntington’s disease pa-tients and families. Am J Phys Anthropol. 67:185–94, 1985.
Literaturverzeichnis 52
• Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I: Functional decline in Huntington’s disease. Mov Dis-ord. 10:211–214, 1995.
• Flier JS: Clinical review 94: What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab. 83:1407–13, 1998.
• Folstein SE, Jensen B, Leigh RJ, Folstein MF: The measurement of abnormal move-ment: methods developed for Huntington’s disease. Neurobehavioral Toxicology and Teratology. 5:605-609, 1983.
• Foroud T, Gray J, Ivashina J, Conneally PM: Differences in duration of Hunting-ton’s disease based on age at onset. J Neurol Neurosurg Psychiatry. 66:52–56, 1999.
• Frederich RC, Hamann A, Anderson S, Lollman B: Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1:1311–
14, 1995
• Frederich RC, Hamann A, Anderson S, Lollman B: Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1:1311–
14, 1995.
• Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Na-ture. 395:763–70, 1998.
• Friedman JM, Leibel RL: Tackling a weighty problem. Cell. 69:217-220, 1992.
• Garron DC: Behavioral aspects of Huntington’s chorea. Adv Neurol. 1:729–735, 1973.
• Ge H, Huang L, Pourbahrami T, and Li C: Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem. 277:45898–45903, 2002.
• Greenamyre JT, Shoulson I: Huntington’s disease. In: Calne DB: Neurodegenerative Diseases. WB Saunders, Philadelphia. 685-704, 1994.
• Grinspoon S, Gulick T, Askari H, Landt M, Lee K, Anderson E, Ma Z, Vignati L, Bowsher R, Herzog D, Klibanski A: Serum leptin levels in women with anorexia ner-vosa. Journal of Clinical Endocrinology and Metabolism. 81:3861–3863, 1996.
Literaturverzeichnis 53
• Haines JL, Conneally PM: Causes of death in Huntington disease as reported on death certificates. Genet Epidemiol. 3:417-423, 1986
• Halaas J, Gajiwala K, Maffei M, Cohen S, Chait B, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:543–46, 1995.
• Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM:
Physiological response to longterm peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci . 94:8878–83, 1998.
• Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J: Rate and correlates of weight change in Huntington’s disease. J Neurol Neurosurg Psychiatry.
75:209-212, 2004.
• Harper PS, Shaw D: Huntington’s disease: genetic and molecular studies. In: Harper PS, Edt., Huntington’s disease, 2nd Edition. W.B. Saunders Company Ltd., 260-261, 1996.
• Harper PS: Huntington’s Disease: Second Edition. London: Saunders, 1996.
• Harper PS: The epidemiology of Huntington’s disease. Human Genetics. 89:365-376, 1992.
• Hellström L, Wahrenberg H, Hruska K, Reynisdottir S, Arner P: Mechanisms be-hind gender differences in circulating leptin levels. Journal of Internal Medicine.
247:457–462, 2000.
• Huntington G: On Chorea. Medical and surgical Reporter. 26:320-321, 1872.
• Huntington’s Disease Collaborative Research Group: A novel gene containing a trinukleotide repeat that is expanded and unstable on Huntington’s disease chromo-somes. Cell. 72:971-983, 1993.
• Illarioshkin SN, Igarashi S, Onodera O, Markova ED, Nikolskaya NN, Tanaka H, Chabrashwili TZ, Insarova NG, Endo K, Ivanova-Smolenskaya IA: Trinucleotide repeat length and rate of progression of Huntington’s disease. Ann Neurol. 36:630–635, 1994.
Literaturverzeichnis 54
• Jason GW, Suchowersky O, Pajurkova EM, Graham L, Klimek ML, Garber AT, Poirier-Heine D: Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. Arch Neurol. 54:1081–1088, 1997.
• Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, Zimmer-man C, Srinidhi J, Sotack J, Gusella J: Trinucleotide repeat length and progression of illness in Huntington’s disease. J Med Genet. 31:872–874, 1994.
• Kirkwood SC, Su JL, Conneally M, Foroud T: Progression of symptoms in the early and middle stages of Huntington’s disease. Arch Neurol. 58:273–8, 2001.
• Kremer HP, Roos RA: Weight loss in Huntington’s disease. Arch Neurol. 49:349, 1992.
• Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S: Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 393:72-76, 1998.
• Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE: Cerebral glucose consumption measured by PET in patients with and without psychiatric symp-toms of Huntington's disease. Psychiatry Research. 29:361-362, 1989.
• Laimer M, Ebenbichler CF, Kaser S, Sandhofer A, Weiss H, Nehoda H, Aigner F, Patsch JR: Weight Loss Increases Soluble Leptin Receptor Levels and the Soluble Re-ceptor Bound Fraction of Leptin. Obesity Res. 10:597-601, 2002.
• Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J: Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Comm. 283:982–988, 2001.
• Lee GH, Proenca R, Montez JM, Carroll K, Darvishzadeh JG, Lee JI, Fried-man JM: Abnormal splicing of the leptin receptor in diabetic mice. Nature. 379:632–
35, 1996.
• Lewis CE, Jacobs DR, McCreath H, Kiefe CI, Schreiner PJ, Smith DE, Wil-liams OD: Weight gain continues in the 1990s: 10-year trends in weight and over-weight from the CARDIA study. Coronary Artery Risk Development in Young Adults.
Am J Epidemiol. 151:1172–81, 2000.
Literaturverzeichnis 55
• Liu C, Liu X, Barry G, Ling N, Maki RA, De Souza EB: Expression and characteri-zation of a putative high affinity human soluble leptin receptor. Endocrinology.
138:3548–3554, 1997.
• Lord GM, Matarese M, Howard JK, Baker RJ, Bloom SR, Lechler RI: Leptin modulates the T-cell immune response and reverses starvation-induced immunosup-pression. Nature. 394:897-901, 1998.
• Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM: Dysregulation of gene expression in the R6/2 model of polyglutamine disease: par-allel changes in muscle and brain. Human Molecular Genetics. 11:1911–1926, 2002.
• MacDougald OA, Hwang CS, Fan H, Lane MD: Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3–L1 adipocytes. Proc Natl Acad Sci. 92:9034–7, 1995.
• Maffei MJ, Halaas J, Ravussin E, Pratley RE, Lee GM, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S: Leptin levels in human and rodent: measurement of plasma leptin and ob mRNA in obese and weight-reduced subjects. Nat Med. 1:1155–
61, 1995.
• Mahant N, McCusker EA, Byth K, Graham S: Huntington’s disease: Clinical corre-lates of disability and progression. Neurology. 61:1085-1092, 2003.
• Mann DR, Johnson AO, Gimpel T, Castracane VD: Changes in circulating leptin, leptin receptor, and gonadal hormones from infancy until advanced age in humans. The Journal of Clinical Endocrinology and Metabolism. 88:3339–3345, 2003.
• Mantzoros CS: The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 130:871–881, 1999.
• Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I: Rate of functional decline in Hunting-ton’s disease. Neurology. 54:452–458, 2000.
• Martin JB, Gusella JF: Huntington’s disease: Pathogenesis and management. New Engl J Med. 315:1267-1276, 1986.
Literaturverzeichnis 56
• Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, Zappacosta S: Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Im-munol. 23:182-187, 2002.
• Matsumura K, Tsuchihashi T, Abe I: Central cardiovascular action of neuropeptide Y in conscious rabbits. Hypertension. 36:1040–1044, 2000.
• Mazurek MF, Garside S, Beal MF: Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann Neurol. 41:540-7, 1997.
• Morales LM, Estevez J, Suarez H, Villalobos R, Chacin DB, Bonilla E: Nutritional evaluation of Huntington disease patients. American Journal of Clinical Nutrition. 50:
145–150, 1989.
• Morales LM, Estevez J, Suarez H, Villalobos R, Chacín de Bonilla L, Bonilla E:
Nutritional evaluation of Huntington’s disease patients. Am J Clin Nutr. 50:145–50, 1989.
• Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 344:541–544, 1990.
• Myers RH, Sax D, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pet-tengill FK, Bird ED: Factors associated with slow progression in Huntington’s disease.
Arch Neurol. 48:800–804, 1991.
• NHANES III: National Center for Health Statistics. Health, United States. 1995. Hy-attsville: Public Health Service, 1996.
• Otto K, Cuntz U, Freuhauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M: Weight gain decreases elevated plasma ghrelin con-centrations of patients with anorexia nervosa. European Journal of Endocrinology. 145 669–673, 2001.
• Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science.
269:540-543, 1995.
• Penney JB Jr., Vonsattel JP, MacDonald ME, Gusella JF, Myers RH: CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neu-rol. 41:689–692, 1997.
Literaturverzeichnis 57
• Penney JB, Young AB, Shoulson I, Starosta-Rubenstein S, Snoodgrass SR, San-chez-Ramos J: Huntington’s Disease in Venezuela: 7 years of follow-up on sympto-matic and asymptosympto-matic individuals. Movement disorders. 5:93-99, 1990
• Popovic, V, Svetel, M, Djurovic, M, Petrovic, S, Doknic, M, Pekic, S, Miljic, D, Mi-lic, N, Glodic, J, Dieguez, C, Casanueva, FF, Kostic, V: Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease.
Eur J Endocrinol. 151:451-455, 2004.
• Pratley RE, Salbe AD, Ravussin E, Caviness JN: Higher sedentary energy expendi-ture in patients with Huntington’s disease. Annals of Neurology. 47:64–70, 2000.
• Quarrell O, Harper PS: Clinical neurology of Huntington’s disease. In: Harper PS, ed.
Huntington’s disease. 2nd ed. London: WB Saunders. 1996.
• Quian H, Azani MJ, Compton MM, Hartzell D, Hausman GH, Baile CA: Brain administration causes deletion of adipocytes by apoptosis. Endocrinology. 139:791–94, 1997.
• Quinton ND, Smith RF, Clayton PE, Gill MS, Shalet S, Justice SK, Simon SA, Walters S, Postel-Vinay MC, Blakemore AIF, Ross RJM: Leptin Binding Activity Changes with Age: The Link between Leptin and Puberty. J Clin Endocrinol Metab.
84:2336-2341, 1999.
• Ridley RM, Frith CD, Farrer LA, Conneally PM: Patterns of inheritance of the symptoms of Huntington’s disease suggestive of an effect of genomic imprinting. J Med Genet. 28:224-231, 1991.
• Robbins AO, Ho AK, Barker RA: Weight changes in Huntington's disease . European Journal of Neurology. 13:e7, 2006.
• Sanberg PR, Fibiger HC, Mark RF: Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust. 1:407–9, 1981.
• Sanberg PR, Fibiger HC, Mark RF: Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust. 1:407–409, 1981.
• Schinke M, Baltatu O, Bohm M, Peters J, Rascher W, Bricca G, Lippoldt A, Gan-ten D, Bader M: Blood pressure reduction and diabetes insipidus in transgenic rats de-ficient in brain angiotensinogen. Proc Natl Acad Sci U S A. 96:3975–3980, 1999.
Literaturverzeichnis 58
• Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A: Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron. 14:1065–1074, 1995.
• Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayas-hi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K: Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin ac-tion through the activaac-tion of hypothalamic neuropeptide Y/Y1 receptor pathway. Dia-betes. 50:227–232, 2001.
• Shoulson I, Miller C, Welle S, et al.: Huntington’s disease: body weight and basal metabolic indices. Ann Neurol. 16:126, 1984.
• Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA: Unified Hunting-ton’s disease rating scale: a follow up. Mov Disord. 13:915–919, 1998.
• Sinha MK, Opentanova I, Ohannesian JP, Kolacynski JW, Hale L, Becker GW, Bowsher RR, Stephens TW, Caro JF: Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin In-vest. 98:1277–82, 1996.
• Snehalatha C, Ramachandran A, Satyavani K, Sivasankari S, Vijay V: Difference in body fat percentage does not explain the gender dimorphism in leptin in Asian In-dians. J Assoc Physicians India. 47:1164-7, 1999.
• Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture.
Cell. 87:377–89, 1996.
• Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K, Koletsky RJ:
Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet. 14:130–31, 1996.
• Tartaglia L, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, Tepper RI: Identification and expres-sion cloning of a leptin receptor. Cell. 83:1263–71, 1995.
• Telenius H, Kremer HP, Theilmann J, Andrew SE, Almquist E, Anvret M, Green-berg C, GreenGreen-berg J, Lucotte G, Squitieri F: Molecular analysis of juvenile
Hunting-Literaturverzeichnis 59
ton’s disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Human Molecular Genetics. 2:1535-40, 1993.
• Trejo A, Boll MC, Alonso ME, Ochoa A, Velásquez L: Use of oral nutritional supp-lements in patients with Huntington’s disease. Nutrition. 21:889-894, 2005.
• Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velásquez L: Assessment of the nutrition status of patients with Huntington's disease. Nutrition. 20:192-196, 2004.
• Tyler AI, Salmon DP, McCullough D, Butters N: A comparison of the category flu-ency deficits associated with Alzheimer’s and Huntington’s disease. Brain and Lan-guage. 37:550-513, 1998.
• van Dijk JG, van der Velde EA, Roos RA, Bruyn GW: Juvenile Huntington disease.
Hum Genet. 73:235–239, 1986.
• Villafuerte BC, Fine JB, Bai Y, Zhao W, Fleming S, DiGirolamo M: Expressions of Leptin and Insulin-Like Growth Factor-I Are Highly Correlated and Region-Specific in Adipose Tissue of Growing Rats. Obesity Res. 8:646-655, 2000.
• von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AMM, Paul M, Jones L, Lin-denberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O: Transgenic rat model of Huntington’s disease. Hum Mol Gen. 12:617–624, 2003.
• Walker DA, Harper PS, Wells CGC, Tyler A, Davies K, Newcombe RG: Hunting-ton’s chorea in South Wales. A genetic and epidemiological study. Clinical Genetics.
19:213-221, 1981.
• Wang MY, Zhou YT, Newgard CB, Unger RH: A novel leptin receptor isoform in rat. FEBS Lett. 392:87–90, 1998.
• Weigle DS, Bukowski TR, Foster DC, Holderman S, Kramer JM, Lasser G, Lofton-Day CE, Prunkard DE, Raymond C, Kuijper JL: Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. Journal of Clinical Investigation.
96:2065-2070, 1995.
Literaturverzeichnis 60
• Weindl A, Conrad B: Chorea und choreatische Bewegungsstörungen. In: Conrad B, Ceballos-Baumann AO, Hrsg. Bewegungsstörungen in der Neurologie. Thieme. 155-180, 1996.
• White DW, Wang DW, Chua SC Jr, Morgenstern JP, Leibel RL: Constitutive and impaired signaling of leptin receptors containing the Gln-Pro extracellular domain mu-tation. Proc Natl Acad Sci. 94:10657–62, 1997.
• Williamson DF: Descriptive epidemiology of body weight and weight change in US adults. Ann Intern Med. 119:646–9, 1993.
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425–32, 1994.
Lebenslauf 61